

Vistogard (uridine triacetate)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Vistogard 10-gm single dose packets	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Vistogard (uridine triacetate) may be approved if the following criteria are met:

- I. Individual is using for the emergency treatment of fluorouracil or capecitabine overdose, regardless of the presence of symptoms;
OR
- II. Individual exhibits early-onset, severe or life-threatening toxicity to fluorouracil or capecitabine, affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions;

AND

- III. Therapy is initiated within 96 hours following the end of fluorouracil or capecitabine administration.

Requests for Vistogard may not be approved for the following:

- I. For nonemergent treatment of adverse reactions associated with fluorouracil or capecitabine; **OR**
- II. If Vistogard is initiated more than 96 hours following the end of fluorouracil or capecitabine administration.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: March 29, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.